Overview of Ebastina Mylan

Property	Description
Active ingredient	Ebastine
Form	Tablet (often film-coated or orodispersible)
Pharmacological class	H1-receptor antagonist (Antihistamine)
General purpose	Symptomatic treatment of allergic reactions
Origin	Synthetic piperidine derivative

Ebastina Mylan is a single-ingredient pharmaceutical product defined by the active ingredient Ebastine, which places it in the high-level class of Antihistamines. This medicine is a synthetic piperidine derivative, designed for oral administration as a tablet. Its general purpose is to provide systemic anti-allergic relief and it is often clinically recognized as a useful option for patients experiencing symptoms characteristic of long-lasting allergic conditions.

What Type of Medicine is Ebastina Mylan?

The active substance, Ebastine, is pharmacologically classified as a second-generation H1-receptor antagonist. This class signifies a potent, highly selective antagonism of the histamine H1 receptor located in the body's periphery. Pharmacological studies have consistently confirmed that Ebastine binds preferentially to peripheral H1 receptors in vivo. The structural design of this compound ensures the molecule has minimal passage across the blood-brain barrier, which is a defining feature that separates second-generation compounds from older sedating antihistamines.

Composition and Form of Ebastina Mylan

The core composition contains only the single active ingredient, Ebastine, along with the necessary solid excipient matrix to form the pill. The medicine is delivered as a pharmaceutical preparation via the oral route, often available as a standard film-coated tablet or a rapidly dissolving orodispersible tablet. Following oral administration, Ebastine is rapidly and extensively metabolized to its primary therapeutic compound, Carebastine, which is responsible for the prolonged anti-allergic effects. This conversion to an active metabolite allows for the medicine's extended therapeutic duration.

What Is the General Purpose of This Antihistamine?

The general therapeutic purpose of this medicine is to provide effective symptomatic treatment of allergies by mitigating the physiological effects of histamine. Ebastine achieves this through selective peripheral H1 antagonism, a mechanism that directly interrupts the process where histamine, a key chemical mediator, binds to and activates its target receptors. The effectiveness of Ebastine in the symptomatic management of allergies has been clinically recognized in comparative studies against other compounds in its class.

What side effects are possible with Ebastina Mylan?

Adverse Reactions and Safety Profile

Official regulatory documents classify adverse reactions to Ebastina Mylan by frequency and System-Organ Class. The most Common effects, potentially affecting up to 1 in 10 users, include headache, drowsiness, and dry mouth.

Adverse Reaction Frequency

Frequency	Examples
Very Common ( > 1 in 10)	Headache
Common (up to 1 in 10)	Drowsiness, Dry mouth
Rare (up to 1 in 1,000)	Hypersensitivity reactions (including anaphylaxis, angioedema), Tachycardia, Palpitations, Hepatitis, Cholestasis, Abnormal liver function tests, Edema, Nervousness, Insomnia
Not Known (cannot be estimated)	Increased appetite, Weight increased

Clinically Significant Safety Information

Serious Adverse Reactions: Rare but clinically significant reactions documented include severe hypersensitivity reactions (such as anaphylaxis and angioedema) and hepatobiliary disorders (including hepatitis, cholestasis, and abnormal liver function test results).

Special Safety Precautions: Caution is advised in patients with known prolongation of the QTc interval on the ECG, hypokalemia, or when co-administering with medicines known to prolong the QTc interval or inhibit the CYP3A4 enzyme system (e.g., certain azole antifungals and macrolide antibiotics). Concomitant use with these specific interacting agents may lead to increased Ebastina plasma levels and heightened cardiac risk.

Population-Specific Restrictions: The medicine is generally contraindicated in children under 12 years of age due to lack of established safety and efficacy. In patients with severe hepatic impairment, the dose should not exceed 10 mg daily.

Overdose and Emergency Response

Overdose and when to seek help

In the event of a suspected overdose of Ebastina Mylan, immediate professional medical assistance must be sought. The official regulatory profile for Ebastine overdose is defined by the absence of a specific antidote. Consequently, management is entirely symptomatic and supportive, and treatment should be maintained until complete recovery.

Documented Manifestations and Risks

Official regulatory documents state that an overdose may increase the risk of sedation and antimuscarinic effects. While studies with single doses up to 100 mg have generally shown no clinically significant signs or symptoms, a minor, statistically significant increase of 10 ms in the QTc interval was noted. The development of central nervous symptoms is the official criterion that may necessitate intensive care.

Required Emergency Actions

When a suspected overdose occurs, specific procedural steps must be carried out, as mandated by regulatory authorities. These measures include gastric lavage, together with continuous monitoring of vital functions. Hospital observation is required, specifically involving ECG monitoring with the evaluation of the QT interval for at least 24 hours. This stringent monitoring is required to manage potential cardiac effects, as management relies solely on supportive care.

Therapeutic Uses of Ebastina Mylan

Main Uses of Ebastina Mylan

Ebastina Mylan is a second-generation antihistamine used to manage symptoms associated with allergic reactions. Its primary function is to block the effects of histamine, a substance naturally produced by the body during an immune response to allergens.

Allergic Rhinitis

This medication is frequently used to alleviate symptoms of allergic rhinitis, which can be either seasonal or perennial. It addresses various nasal and ocular symptoms, including:

Nasal congestion and sneezing: Reducing the inflammation and irritation in the nasal passages.
Rhinorrhea: Controlling the excessive production of nasal mucus (runny nose).
Itching: Relieving pruritus in the nose and throat.
Ocular symptoms: Managing redness, watering, and itching of the eyes often associated with hay fever.

Urticaria

Ebastina Mylan is also indicated for the treatment of urticaria, commonly known as hives. It helps manage chronic idiopathic urticaria by reducing the physical manifestations of the condition, such as:

Wheals: Minimizing the appearance of raised, itchy red welts on the skin.
Skin Irritation: Alleviating the localized swelling and intense itching sensation associated with hives.

Therapeutic Benefits

As a long-acting antihistamine, Ebastina Mylan offers specific therapeutic characteristics for patients managing allergic conditions:

Non-Sedating Profile: Unlike first-generation antihistamines, it is designed to have a limited ability to cross the blood-brain barrier, which typically results in a lower incidence of drowsiness at recommended therapeutic levels.
Prolonged Action: The medication provides a sustained effect, allowing for symptom control over a 24-hour period with a single application.
Selective Histamine Blockade: It specifically targets H1 receptors, which are responsible for the immediate hypersensitivity reactions seen in allergies, while having minimal impact on other systems in the body.

Eligibility and Restrictions for Use

Populations for Whom Use is Defined

The regulatory profile for Ebastina Mylan establishes specific eligibility and non-eligibility rules. Absolute contraindications prohibit use in patients with known hypersensitivity to ebastine or any excipients, as well as in those with rare hereditary issues like galactose intolerance if the tablet contains lactose.

Age-related eligibility permits standard use for adults and adolescents 12 years and above; however, safety and efficacy have not been established in children under 12 years of age. For chronic urticaria, use is typically restricted to adults geq 18 years.

Condition-specific eligibility requires caution in patients with a known risk of QTc interval prolongation or Hypokalaemia. While use is permitted in all degrees of renal impairment and in mild to moderate hepatic impairment with no required dose adjustment, use is restricted in severe hepatic impairment (the maximum dose must not be exceeded).

Pregnancy and lactation eligibility status is defined by precautionary avoidance; use is not recommended due to limited human safety data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Ebastina is primarily defined by its metabolism through the hepatic Cytochrome P450 enzyme system, specifically the CYP3A4, CYP2J2, and CYP4F12 enzymes.

Interacting Agents
Potent CYP Inhibitors: Azole antifungals (e.g., Ketoconazole, Itraconazole) and Macrolide antibiotics (e.g., Erythromycin, Clarithromycin).
QTc-Prolonging Medicinal Products: Specific drugs known to prolong the QTc interval.
CYP Inducers: Anti-tuberculosis agents (e.g., Rifampicin).

Co-administration with potent inhibitors of the CYP3A4, CYP2J2, or CYP4F12 enzymes, such as Ketoconazole or Erythromycin, results in elevated plasma concentrations of Ebastine and its active metabolite, Carebastine. While clinical studies showed this did not lead to a clinically significant pharmacodynamic consequence on the QTc interval, the official regulatory documents advise caution with such combinations, particularly in patients with predisposing risk factors for QTc prolongation.

Conversely, co-administration with enzyme inducers, such as Rifampicin, causes reduced plasma concentrations of Ebastine, which is documented to result in a reduction of the drug's intended antihistamine effects. Food intake has been shown to increase the main metabolite's plasma levels, though no change in clinical effect was noted. No interaction was reported with common agents such as Warfarin, Theophylline, or Cimetidine.

Mechanism of Action

Selective Blockade of Peripheral H1 Receptors

The primary mechanism of action is defined by its active metabolite, Carebastine, which functions as a selective antagonist (blocker) of the peripheral histamine H1 receptors. This molecular interaction prevents the endogenous mediator histamine from binding to the receptor, thereby suppressing the activation of the histamine-mediated signaling cascade in peripheral tissues.

Modulation of Microvascular and Neuronal Pathways

By maintaining a sustained presence at the H1 receptor, the drug attenuates the H1-mediated signaling for vasodilation (widening of blood vessels) and increased vascular permeability (fluid leakage). This action, combined with the suppression of H1-mediated peripheral neuronal activation, modulates the H1-driven physiological responses in the microvasculature and nerve tissues.

Prodrug Activation and CNS Specificity

Ebastina Mylan is administered as a prodrug (Ebastine) that undergoes rapid metabolic conversion to the active therapeutic species, Carebastine, to produce a sustained receptor blockade. The structure of Carebastine ensures a functional mechanistic limitation by preventing its significant passage across the blood-brain barrier ( BBB), which confines the H1 receptor blockade strictly to the body's periphery.

Dosage and Administration Information

Ebastina Mylan (ebastine) is administered via the oral route as a once-daily dose.

Official Dosing and Administration

The standard dosing for the medicine is a fixed daily regimen:

Population	Standard Dosing Regimen	Maximum Recommended Dose
Adults and Adolescents (≥ 12 years)	10 mg once daily	20 mg once daily (for severe symptoms)
Adults (≥ 18 years) for Urticaria	10 mg once daily	10 mg once daily

Administration Conditions and Special Populations

Timing and Intake: The medicine can be taken independently of meals (with or without food). Film-coated tablets should be swallowed whole with liquid. Orodispersible tablets are placed on the tongue to disperse and do not require water.

Dose Adjustments:

Renal Impairment: No dose adjustment is necessary for patients with mild, moderate, or severe renal impairment.
Severe Hepatic Impairment: The dose should not exceed 10 mg once daily, as there is limited experience with higher doses in this specific population.

Course Duration: The duration of use is determined by the prescribing physician and may be prolonged until symptoms resolve. If a dose is missed, it is advised to take the next scheduled dose at the usual time and not take a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section provides an overview of the research studies that have investigated patient outcomes associated with Ebastina Mylan. This summary describes research findings; all treatment decisions require consultation with a healthcare professional.

Research has explored whether the drug is associated with a reduction in allergic rhinitis and chronic urticaria symptoms. Some studies have investigated whether the drug was associated with rapid changes in symptoms reports.

Study A: Dosage and Efficacy Investigation

Randomized controlled trials (RCTs) examined whether the 10 mg dose was associated with a different outcome compared to other doses. Some studies comparing a 20 mg dose to a 10 mg dose or other second-generation antihistamines have noted trends toward greater efficacy with the higher dose in seasonal allergic rhinitis, though statistical significance has varied across trials.

Studies investigating acute urticaria have reported changes in itching and wheal reports within the first week of use.

Study B: Long-term Safety and Efficacy Evaluation

Phase 3 trials reported findings on changes in symptoms and biomarkers over a 12-week to 12-month period in perennial allergic rhinitis. Control of symptoms was observed to persist over the 12 weeks of the study period.

Research has evaluated the drug in individuals with mild to moderate liver impairment and renal impairment. Pharmacokinetic studies suggest that the drug's exposure is not significantly altered in patients with mild to moderate impairment compared to healthy volunteers. The trials did not study the effects of doses over 10 mg in people with severe liver impairment.

Study C: Combination Therapy Outcomes Investigation

Research explored whether the drug's use alongside other treatments (e.g., decongestants) was associated with different outcomes compared to use as monotherapy.

The trial's findings included a comparison of the combined approach versus other approaches. The trial's findings provided data for comparison of the combined approach versus other approaches in treating allergic rhinitis.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ebastina Mylan (FAQ)

Q: How quickly does Ebastina Mylan start to work after taking it?

Studies included in the official product information indicate that a statistically significant antihistamine effect is reported to begin 1 hour after the medicine is administered. This is a result of the rapid conversion of the inactive drug into its active therapeutic form in the body.

Q: Is it normal to feel a bit tired when first taking Ebastina Mylan?

Drowsiness (somnolence) is listed in regulatory documents as a common side effect of this medicine. Drowsiness is a documented reaction, but official information does not clarify if the feeling is more common upon starting treatment versus continued use.

Q: What types of medications are known to interact with Ebastina Mylan?

Official documents describe interactions mainly with potent inhibitors of the CYP450 enzyme system, such as certain azole antifungals and macrolide antibiotics. Caution is also advised when using it alongside other medicines known to affect the heart's rhythm (prolong the QTc interval). It is important for a healthcare professional to assess all medications for potential interactions.

Q: Is it true that this drug can affect heart rhythm?

Official warnings advise caution for individuals with certain pre-existing heart rhythm issues, specifically known prolongation of the QTc interval on the ECG. Rare side effects documented in official reports include tachycardia (fast heart rate) and palpitations.

Q: Can I take Ebastina Mylan if I am pregnant or breastfeeding?

Official product information states that use during both pregnancy and lactation (breastfeeding) is generally not recommended. This is a precautionary avoidance due to the limited amount of human safety data available.

Q: What is the expected duration of the anti-allergic effect of one dose?

Studies show that the anti-allergic effect of a single dose of Ebastina Mylan lasts for more than 24 hours. The drug is designed to provide a prolonged effect through a sustained blockade of histamine receptors in the body.

Q: Is it considered a long-acting allergy medication?

Yes, regulatory documents classify this medicine as a selective antihistamine with prolonged effects. This characteristic allows it to be taken only once daily for the management of symptoms.

Q: Can people with known heart conditions be prescribed Ebastina Mylan?

Official warnings specifically advise caution for people with known risk factors, such as a prolonged QTc interval. Official guidelines require a healthcare professional to assess the potential risk factors before prescribing.

Q: Can Ebastina Mylan be taken if I am already taking antifungal medicines?

Caution is advised when using this medicine with certain antifungal drugs, such as azole antifungals. Combining these medicines may increase the plasma concentration of Ebastine. Therefore, co-administration should be determined by a healthcare professional.

Q: Can Ebastina Mylan be used for year-round allergies?

According to the official product indication, the medicine is used for the symptomatic treatment of both seasonal allergic rhinitis (like hay fever) and perennial allergic rhinitis (allergies that occur year-round).

Q: Is Ebastina Mylan different from other common allergy pills?

The medicine is classified as a second-generation H1-receptor antagonist. This group of allergy pills is characterized by having minimal ability to cross the blood-brain barrier, which helps to confine its effects to the body’s periphery.

Q: Can you take Ebastina Mylan with pain relievers like paracetamol or ibuprofen?

Official regulatory documents do not specifically report an interaction with pain relievers such as paracetamol or ibuprofen. Clinical studies have reported no interactions with several other common agents like theophylline or warfarin.

Q: Is Ebastina Mylan safe for children to use?

Safety and efficacy are established for adolescents 12 years of age and above, which is the minimum age defined for use in allergic rhinitis. The medicine is generally contraindicated (prohibited) for use in children under 12 years of age.

Q: What is the age limit for taking Ebastina Mylan, according to official documents?

The minimum age for standard use for allergic rhinitis symptoms is 12 years of age. For the treatment of chronic urticaria (hives), official guidelines specify use only for adults aged 18 years and above.

Q: Is there any research on Ebastina Mylan and long-term use?

Yes, research has investigated the effects of the drug over extended periods. Clinical experience is documented for use in allergic rhinitis for durations up to 1 year and for urticaria for up to 3 months. The duration of treatment is determined by the prescriber based on the clinical need.

Q: Does the medicine lose its effect if I take it every day for a long time?

Research indicates that control of symptoms was observed to persist over treatment periods lasting up to 12 weeks. Official regulatory sources do not specifically discuss a loss of effect (known as tachyphylaxis) with long-term, continuous daily use.

Q: Can Ebastina Mylan cause changes in weight?

Increased appetite and weight increase are listed in the adverse reactions section of the product information. However, the frequency of these particular effects is classified as 'Not Known,' meaning it cannot be estimated from the available data.

Q: What is the difference between ebastine and 'Ebastina Mylan'?

Ebastine is the name of the single active ingredient that provides the therapeutic effect. 'Ebastina Mylan' is the specific brand name given to the pharmaceutical product that contains the active ingredient Ebastine.

Q: Does Ebastina Mylan treat asthma or just allergy symptoms?

The official indication for this medicine is strictly for the symptomatic treatment of allergic rhinitis and chronic urticaria. It is not officially indicated for the treatment or management of asthma.

Q: What is the purpose of Ebastina Mylan for treating skin itching?

The medicine is officially indicated 'To improve itching and to reduce new wheal formation in urticaria of unclear origin' (hives). This use is linked to its ability to mitigate the physiological effects of histamine, a key mediator in these conditions.

Q: Can a person who has had an allergic reaction to another antihistamine use Ebastina Mylan?

The medicine is strictly contraindicated (prohibited) if a patient has a known hypersensitivity to ebastine or any of the inactive ingredients in the tablet. It is important to discuss all known drug allergies with a healthcare professional.

Q: Does Ebastina Mylan have a sedative effect that impacts driving or operating machinery?

Official documents generally state that the medicine does not impair the ability to drive or use machines. Due to the potential for some individuals to experience drowsiness or dizziness, caution is advised before operating complicated equipment.

Q: Are there reports of mental or mood changes with Ebastina Mylan?

Reports of nervousness and insomnia (difficulty sleeping) are listed as rare adverse reactions in the official product documents. These potential effects occur in less than 1 in 1,000 users.

Q: Is there a non-drowsy version of ebastine?

Ebastine is pharmacologically classified as a non-sedating antihistamine because its structure restricts passage across the blood-brain barrier. However, official information still lists drowsiness (somnolence) as a common side effect for some people.

Q: Is it common for Ebastina Mylan to be prescribed alongside nasal sprays?

Research has been conducted that explores patient outcomes when this medicine is used alongside other common treatments, such as decongestants, compared to use alone. Official documents do not define common prescribing practice or frequency.

Q: How does Ebastina Mylan compare to older generations of allergy medication?

Ebastine is classified as a second-generation H1-receptor antagonist. This class is distinguished from older, first-generation antihistamines because its chemical structure results in minimal passage across the blood-brain barrier.

Q: Why are people with known low potassium levels sometimes advised caution?

Official guidelines advise caution for patients with hypokalaemia (low blood potassium levels). This is because low potassium levels are considered a risk factor that could potentially contribute to prolongation of the QTc interval, an electrical measurement of the heart which is a specific area of precaution for this medicine.

Q: What are the signs of an overdose described in official documents?

Studies involving high daily dosages did not consistently observe any clinically meaningful signs or symptoms of overdose. Official overdose guidelines advise monitoring a patient’s vital functions, particularly their heart activity (ECG).

How should Ebastina Mylan be stored and disposed of?

How to Store and Dispose of Ebastina Mylan?

Official regulatory documents specify mandatory conditions for the storage and disposal of Ebastina Mylan tablets to ensure product stability and environmental safety.

Required Storage Conditions

Requirement	Official Regulatory Statement
Temperature Control	Store the product below 25 C (77°F).
Container Rule	Keep the medicine in its original container to protect it from moisture.
Safety Rule	Keep the tablets out of the sight and reach of children.

Disposal Instructions

Used or expired Ebastina Mylan must not be disposed of via wastewater or household waste. Disposal of any unused medicine or waste material must be carried out strictly according to local requirements for pharmaceutical waste.

Ebastina Mylan